BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2512681)

  • 1. The differential glycosylation of human pro-urokinase from various recombinant mammalian cell lines does not affect activity and binding to PAI-1.
    Sarubbi E; Nolli ML; Robbiati F; Soffientini A; Parenti F; Cassani G
    Thromb Haemost; 1989 Nov; 62(3):927-33. PubMed ID: 2512681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3).
    Ugwu F; Van Hoef B; Bini A; Collen D; Lijnen HR
    Biochemistry; 1998 May; 37(20):7231-6. PubMed ID: 9585535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential detection of single-chain and two-chain urokinase-type plasminogen activator by a new immunoadsorbent-amidolytic assay (IAA).
    Corti A; Nolli ML; Cassani G
    Thromb Haemost; 1986 Dec; 56(3):407-10. PubMed ID: 3105110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
    Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
    Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Native and non-glycosylated recombinant single-chain urokinase-type plasminogen activator are recognized by different receptor systems on rat parenchymal liver cells.
    van der Kaaden ME; Rijken DC; Groeneveld E; van Berkel TJ; Kuiper J
    Thromb Haemost; 1995 Aug; 74(2):722-9. PubMed ID: 8585013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of human single chain urokinase to Chinese Hamster Ovary cells and cloning of hamster u-PAR.
    Fowler B; Mackman N; Parmer RJ; Miles LA
    Thromb Haemost; 1998 Jul; 80(1):148-54. PubMed ID: 9684801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM; Dosne AM; Kher A; Samama M
    Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assay method for single-chain urokinase-type plasminogen activator.
    Matsuo O; Ueshima S; Okada K; Fukao H; Ohgaki M; Watanabe R; Arimura H
    Hematol Pathol; 1989; 3(3):137-42. PubMed ID: 2531734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrin specific thrombolysis by two-chain urokinase-type plasminogen activator cleaved after arginine 156 by thrombin.
    Abercrombie DM; Buchinski B; Salvato KA; Vovis GF; Stump DC; Broeze RJ
    Thromb Haemost; 1990 Nov; 64(3):426-32. PubMed ID: 2128973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of the activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction of normal plasma and of plasmas deficient in factor XII and prekallikrein.
    Binnema DJ; Dooijewaard G; Turion PN
    Thromb Haemost; 1991 Feb; 65(2):144-8. PubMed ID: 1905069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
    Fry ET; Mack DL; Sobel BE
    Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of cell-associated plasminogen activation by stromelysin-1 (MMP-3).
    Ugwu F; Lemmens G; Collen D; Lijnen HR
    Thromb Haemost; 1999 Sep; 82(3):1127-31. PubMed ID: 10494776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New thrombolytic agents].
    Nguyen G; Samama M
    Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
    Barnathan ES; Kuo A; Rosenfeld L; Karikó K; Leski M; Robbiati F; Nolli ML; Henkin J; Cines DB
    J Biol Chem; 1990 Feb; 265(5):2865-72. PubMed ID: 2154462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human hepatoma cell line plasminogen activator.
    Levin EG; Fair DS; Loskutoff DJ
    J Lab Clin Med; 1983 Oct; 102(4):500-8. PubMed ID: 6311924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative kinetic analysis of the activation of human plasminogen by natural and recombinant single-chain urokinase-type plasminogen activator.
    Lijnen HR; Van Hoef B; Collen D
    Biochim Biophys Acta; 1986 Dec; 884(3):402-8. PubMed ID: 3778931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A plasminogen activator inhibitor-2 from a promyelocytic leukemia cell line, PL-21, binds to the carboxy-terminal chain of plasminogen activators.
    Takeuchi T; Niiya K; Kubonishi I; Miyoshi I
    Thromb Haemost; 1990 Apr; 63(2):259-64. PubMed ID: 2363126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the in vitro fibrinolytic activities of low and high molecular weight single-chain urokinase-type plasminogen activator.
    de Munk GA; Groeneveld E; Rijken DC
    Thromb Haemost; 1993 Sep; 70(3):481-5. PubMed ID: 8259553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.